SHEUR

Pre-Launch

elagolix, estradiol and norethindrone acetate and elagolix

ANDACAPSULE

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

SHEUR (elagolix, estradiol and norethindrone acetate and elagolix) by Teva is gland. Approved for moderate to severe pain associated with endometriosis.

Drug data last refreshed 1mo ago

Mechanism of Action

gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.

Indications (1)

moderate to severe pain associated with endometriosis

Company

Worked on SHEUR at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.